Protective Effect of Atazanavir Sulphate Against Pulmonary Fibrosis In Vivo and In Vitro.
Song S, Ji Y, Zhang G, Zhang X,
Basic Clin Pharmacol Toxicol. 2017 Aug 16.
Abstract

Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients
Rigo F, Cucchetto G, Lanzafame M, et al 
HIV Med. 2017 May 15.
Abstract

Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A, Ismail A, Abushouk AI, et al
Arch Virol. 2017 Mar 30
Abstract

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Marinaro L, Calcagno A, Ripamonti D,  et al
J Clin Virol. 2016 Dec 1;87:30-36. doi:
Abstract

Atazanavir plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
Gallant JE, Moyle G, Berenguer J,  et al  
 Curr HIV Res. 2016 Oct 21
Abstract

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L, Landman R, Assoumou L, et al
J Antimicrob Chemother. 2016 Apr 10
Abstract

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
Crutchley RD, Guduru RC, Cheng AM.
HIV AIDS (Auckl). 2016 Mar 9;8:47-65.
Abstract

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A,  et al
J Antimicrob Chemother. 2016 Mar
Abstract

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Teófilo E, Rocha-Pereira N, Kuhlmann B,
HIV Clin Trials. 2016 Jan;17(1):17-28.
Abstract

FULL-TEXT PDF ARTICLE
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
Tsai MS, Chang SY, Lin SW,
J Microbiol Immunol Infect. 2016 Jan 11. pii: S1684-1182(16)00014-1.
Paper

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Postorino MC, Prosperi M, Quiros-Roldan E, et al
Clin Microbiol Infect. 2014 Nov 11.
Abstract

A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
Sevinsky H, Tao X, Wang R,  et al.
Antivir Ther. 2014 Oct 31.
Abstract

Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up.
Lanzafame M, Lattuada E, Rigo F, et al
J Antimicrob Chemother. 2014 Oct 8.
Abstract

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial.
Lennox JL, Landovitz RJ, Ribaudo HJ,  et al
Ann Intern Med. 2014 Oct 7;161(7):461-71.
Abstract

Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients.
Bonora S, Calcagno A, Vigano O,  et al
 Curr HIV Res. 2014 Aug 7
Abstract

Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
Wang Q, Young J, Bernasconi E, Vernazza P, et al
HIV Clin Trials. 2014 May-Jun;15(3):92-103.
Abstract

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I, Hernández-Novoa B, Alejos B, et al
HIV Med. 2014 Mar 24.
Abstract

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J, Conway B, Giguère P,  et al
HIV Med. 2013 Dec 9.
Abstract

Outcomes by Sex following Treatment Initiation with Atazanavir plus Ritonavir or Efavirenz with Abacavir/Lamivudine or Tenofovir/Emtricitabine.
Smith KY, Tierney C, Mollan K, et al
Clin Infect Dis. 2013 Nov 18.
Abstract

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI, Dunn DT, Sutherland KA,  et al
J Antimicrob Chemother. 2013 May 27.
Abstract

An unusual case of HIV virologic failure during treatment with boosted atazanavir.
Duncan A, Mills J.
AIDS. 2013 May 15;27(8):1361-2.
Abstract

A Maintenance Dose of Atazanavir/Ritonavir 200/100 mg Once Daily Is Effective in Virologically Suppressed HIV-1-Infected Patients.
Lanzafame M, Lattuada E, Rigo F, Vento S.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e81-2.
Abstract

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results.
Gallant JE, Koenig E, Andrade-Villanueva J,  et a
J Infect Dis. 2013 Apr 19.
Abstract

Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r) - Containing Regimens in Treatment-Experienced Patients with HIV.
Svedhem-Johansson V, Pugliese P,  et al
Curr HIV Res. 2013 Apr 12.
Abstract

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial.
Andersson LM, Vesterbacka J, Blaxhult A,  et al
Scand J Infect Dis. 2013 Jan
Abstract

Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-boosted Atazanavir in AIDS Clinical Trials Group Study A5202.
Ribald HJ, Daar ES, Tierney C,  et al
J Infect Dis. 2012 Nov 12.
Abstract